Table 1.
List of proteins and polypeptides a
| No. | Protein | Reference | PDB | L | ln(kf) | CO, % | Abs_CO |
| 30 | S6 | Otzen and Oliveberg 1999 | 1RIS | 101 (97) | 5.9 | 18.9 | 18.4 |
| 31 | His-containing phosphocarrier protein | Van Nuland et al. 1998b | 1POH | 85 | 2.7 | 17.6 | 15.0 |
| 32 | N-terminal domain from L9 | Kuhlman et al. 1998 | 1DIV | 56 | 6.1 | 12.7 | 7.1 |
| 33 | Villin 14T | Choe et al. 1998 | 2VIK | 126 | 6.8 | 12.3 | 15.4 |
| 34 | Apomyoglobinl | Cavagnero et al. 1999 | 1A6N | 151 | 1.1 | 8.4 | 12.7 |
| 35 | Colicin E7 immunity protein | Ferguson et al. 1999 | 1CEI | 87 (85) | 5.8 | 10.8 | 9.2 |
| 36 | Cro protein | Laurents et al. 2000 | 2CRO | 71 (65) | 3.7 | 11.2 | 7.3 |
| 37 | P16 protein | Tang et al. 1999 | 2A5E | 156 | 3.5 | 5.3 | 8.3 |
| 38 | Twitching Ig repeat 27 | Fowler and Clarke 2001 | 1TIT | 89 | 3.6 | 17.8 | 15.8 |
| 39 | CD2, 1st domain | Parker et al. 1997 | 1HNG | 98 (95) | 1.8 | 16.9 | 16.0 |
| 40 | Fibronectin tenth FN3 module | Cota and Clarke 2000 | 1FNF | 94 | 5.5 | 16.5 | 15.5 |
| 41 | IFABP from rat | Burns et al. 1998 | 1IFC | 131 | 3.4 | 13.5 | 17.7 |
| 42 | ILBPm | Dalessio and Ropson 2000 | 1EAL | 127 | 1.3 | 12.3 ± 0.5 | 15.7 ± 0.6 |
| 43 | CRBP II | Burns et al. 1998 | 1OPA | 133 | 1.4 | 14.0 | 18.7 |
| 44 | CRABP I | Burns et al. 1998 | 1CBI | 136 | −3.2 | 13.8 | 18.8 |
| 45 | tryptophan synthase α-subunitn | Ogasahara and Yutani 1994 | 1QOP | 268 (267) | −2.5 | 8.3 | 22.3 |
| 46 | GroEL apical domain (191–345) | Golbik et al. 1998 | 1AON | 155 | 0.8 | 13.7 | 21.2 |
| 47 | Barstaro | Schreiber and Fersht 1993 | 1BRS | 89 | 3.4 | 11.8 | 10.5 |
| 48 | Che Y | Munoz et al. 1994 | 3CHY | 129 (128) | 1 | 8.7 | 11.2 |
| 49 | Ribonuclease HIp | Parker and Marqusee 1999 | 2RN2 | 155 | 0.1 | 12.4 | 19.3 |
| 50 | DHFR (dihydrofolate reductase)q | Jennings et al. 1993 | 1RA9 | 159 | 4.6 | 14.0 | 22.3 |
| 51 | tryptophan synthase β2-subunitn | Goldberg et al. 1990 | 1QOP | 396 (390) | −6.9 | 8.3 | 32.5 |
| 52 | N-terminal domain from PGK | Parker et al. 1995 | 1PHP | 175 | 2.3 | 11.5 | 20.2 |
| 53 | C-terminal domain from PGKr | Parker et al. 1996 | 1PHP | 219 | −3.5 | 8.0 | 17.4 |
| 54 | Barnase | Matouschek et al. 1990 | 1BNI | 110 (108) | 2.6 | 11.4 | 12.3 |
| 55 | T4 lysozymes | Parker and Marqusee 1999 | 2LZM | 164 | 4.1 | 7.1 | 11.6 |
| 56 | Ubiquitint | Khorasanizadeh et al. 1996 | 1UBQ | 76 | 5.9 | 15.1 | 11.5 |
| 57 | Suc 1u | Schymkowitz et al. 2000 | 1SCE | 113 (101) | 4.2 | 11.8 | 11.9 |
h The folding of mutant protein Y34W was studied experimentally; we used the available PDB structure of wild type in our calculation of CO.
i The folding of mutant protein Y47W was studied experimentally; we used the available PDB structure of this mutant in our calculation of CO.
j The folding of mutant protein F56W was studied experimentally; we used the available PDB structure of mutant Y31H/Q36R in our calculation of CO.
k The folding of mutant protein C21S was studied experimentally; we used the available PDB structure of wild type protein in our calculation of CO.
l We used the available PDB structure of a holoform of myoglobin (but without heme) in our calculation of CO.
m We used the available PDB structure of mutant protein T118S from pig in our calculation of CO instead of the wild type protein from rat
n The folding of protein from Escherichia coli was studied experimentally. We used the available PDB structure of the same protein from Salmonella typhimurium in our calculation of CO.
o The folding of mutant protein C40A/C82A was studied experimentally; we used the available PDB structure of this mutant in our calculation of CO.
p The folding of mutant protein C13A/C63A/C133A was studied experimentally; we used the available PDB structure of wild type protein in our calculation of CO.
q The folding of wild type protein was studied. We used the available PDB structure of mutant protein N37D in our calculation of CO. ln(kf) value refers to the summary rate of two parallel pathways of refolding of DHFR.
r The folding of mutant protein W290Y was studied experimentally. We used the available PDB structure of wild type in our calculation of CO.
s The folding of Cys-free mutant was studied experimentally. We used the available PDB structure of wild-type protein in our calculation of CO.
t The folding of bovine protein F45W mutant was studied experimentally. We used the available PDB structure of WT human protein in our calculation of CO.
u There is only a strand-exchanged form of suc1 dimer in PDB. We used a concatenation of fragment 2–88 of chain C and fragment 89–102 of chain A as a tentative structure of monomeric protein in our calculation of CO.